Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes pheo in a mpc cell and mouse model to conventional chemotherapy

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Martiniova, Lucia ^a,e   Lu, Jie ^b   Chiang, Jeffrey ^c   Bernardo, Marcelino ^c,d   Lonser, Russell ^b   Zhuang, Zhengping ^b   Pacak, Karel ^a  

^a Reproductive and Adult Endocrinology Program Eunice Kennedy Shriver

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LB 1; PHOSPHOPROTEIN PHOSPHATASE 2A; POLO LIKE KINASE 1; PROTEIN MDM2; PROTEIN P53; SERINE; TEMOZOLOMIDE; THREONINE; UNCLASSIFIED DRUG; DACARBAZINE; DRUG DERIVATIVE; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; LIVER METASTASIS; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PHEOCHROMOCYTOMA; PROTEIN PHOSPHORYLATION; TUMOR REGRESSION; ADRENAL TUMOR; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALIA;

ADRENAL GLAND NEOPLASMS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DACARBAZINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MICE; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; SERINE; THREONINE;

EID: 79951965204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014678     Document Type: Article

References (36)

1. Darzynkiewicz Z, Traganos F, Wlodkowic D, (2009) Impaired DNA damage response-an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 625: 143-150.
2. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
3. Shah MA, Schwartz GK, (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7: 2168-2181.
4. Malumbres M, Barbacid M, (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166.
5. Pardee AB, James LJ, (1975) Selective killing of transformed baby hamster kidney (BHK) cells. Proc Natl Acad Sci U S A 72: 4994-4998.
6. Luo J, Solimini NL, Elledge SJ, (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
7. Lapenna S, Giordano A, (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566.
8. Lenders JW, Eisenhofer G, Mannelli M, Pacak K, (2005) Phaeochromocytoma. Lancet 366: 665-675.
9. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812-8818.
10. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346: 1459-1466.
11. Baysal BE, (2008) Clinical and molecular progress in hereditary paraganglioma. J Med Genet 45: 689-694.
12. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, et al. (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91: 4505-4509.
13. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, et al. (2009) The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 94: 2817-2827.
14. Tischler AS, (2008) Pheochromocytoma: time to stamp out "malignancy"? Endocr Pathol 19: 207-208.
15. Mougey AM, Adler DC, (2007) Neuroendocrine tumors: review and clinical update. Hospital Physician 51: 12-20.
16. Huang H, Abraham J, Hung E, Averbuch S, Merino M, et al. (2008) Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113: 2020-2028.
17. Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, et al. (2009) Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 94: 2850-2856.
18. Bravo EL, Kalmadi SR, Gill I, (2009) Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report. Horm Metab Res 41: 703-706.
19. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166.
20. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, et al. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24: 401-406.
21. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, et al. (2009) Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 106: 11697-11702.
22. Powers JF, Evinger MJ, Tsokas P, Bedri S, Alroy J, et al. (2000) Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell Tissue Res 302: 309-320.
23. Mayo LD, Donner DB, (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98: 11598-11603.
24. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M, (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21: 1299-1303.
25. Blagosklonny MV, (2007) Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6: 70-74.
26. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, et al. (2000) Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2: 672-676.
27. Jang YJ, Ji JH, Choi YC, Ryu CJ, Ko SY, (2007) Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A. J Biol Chem 282: 2473-2482.
28. Zhuang Z, Lu J, Lonser R, Kovach JS, (2009) Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome. Cell Cycle 8: 3303-3306.
29. Goodarzi H, Elemento O, Tavazoie S, (2009) Revealing global regulatory perturbations across human cancers. Mol Cell 36: 900-911.
30. Kovach JS, Johnson F, (August14, 2008) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.Patent Cooperation Treaty Appl WO/2008/097561.
31. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
32. Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, et al. (2010) Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer 2010 Nov 22 [Epub ahead of print].
33. Pacak K, Palkovits M, Kvetnansky R, Matern P, Hart C, et al. (1995) Catecholaminergic inhibition by hypercortisolemia in the paraventricular nucleus of conscious rats. Endocrinology 136: 4814-4819.
34. Bazin PL, Cuzzocreo JL, Yassa MA, Gandler W, McAuliffe MJ, et al. (2007) Volumetric neuroimage analysis extensions for the MIPAV software package. J Neurosci Methods 165: 111-121.
35. Martiniova L, Kotys MS, Thomasson D, Schimel D, Lai EW, et al. (2009) Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI. J Magn Reson Imaging 29: 685-691.
36. Chiang YJ, Hsiao SJ, Yver D, Cushman SW, Tessarollo L, et al. (2008) Tankyrase 1 and tankyrase 2 are essential but redundant for mouse embryonic development. PLoS One 3: e2639.